SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study

Weight loss from diet, exercise, and bariatric surgery consistently increases serum testosterone in men with functional hypogonadism. There is little information about how medications that result in weight loss affect testosterone. Many men with Type 2 Diabetes Mellitus (T2DM) are now taking Glucagon-Like Peptide-1 (GLP-1) Agonists and having benefits on their weight. One study showed a decrease in the diurnal variation of serum testosterone in men taking GLP-1 therapy for 24 hours. The aim of this prospective cohort study was to uncover the effects of GLP-1 therapy on serum testosterone. Between 2015 and 2018, 44 men with T2DM who were beginning GLP-1 therapy had baseline testosterone levels prior to therapy and testosterone levels again after 6-12 months of therapy. On average, participates lost 5 pounds and their A1C values improve by 0.7%. There was no significant change in free or total testosterone values. Average free testosterone was 65pg/dL at baseline and was 59pg/dL at follow-up. Average total testosterone was 333ng/dl at baseline and 335ng/dL at follow-up.